{
    "clinical_study": {
        "@rank": "43644", 
        "arm_group": [
            {
                "arm_group_label": "Baclofen Dose1", 
                "arm_group_type": "Active Comparator", 
                "description": "The subjects will receive baclofen dose 1 for once a day oral administration"
            }, 
            {
                "arm_group_label": "Baclofen dose 2", 
                "arm_group_type": "Active Comparator", 
                "description": "The subjects will receive baclofen dose 1 for once a day oral administration"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a double-blind, randomized, placebo-controlled trial to evaluate duration of action\n      of Baclofen ER capsules (GRS) compared with placebo in subjects with spasticity due to\n      Multiple sclerosis.\n\n      The trial will include male and female subjects greater than or equal to 18 years of age\n      with spasticity with multiple sclerosis."
        }, 
        "brief_title": "Action of Baclofen Capsules in Spasticity Due to Multiple Sclerosis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spasticity", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Muscle Spasticity", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This clinical trial will be conducted in compliance with the Code of Federal Regulations of\n      the United States of America, the guidance and rules of the International Conference on\n      Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use\n      (ICH), the Declaration of Helsinki, and all applicable regulatory requirements.\n\n      This trial is designed to evaluate the duration of the anti-spasticity action of a single\n      dose of Baclofen ER Capsules (GRS) administered in subjects with spasticity due to multiple\n      sclerosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women greater than or equal to 18 years of age\n\n          -  Willing to sign the informed consent form\n\n          -  Women of child bearing potential willing to practice an acceptable method of birth\n             control\n\n          -  Known history of spasticity due to MS\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to baclofen\n\n          -  Treated with intrathecal baclofen prior to study\n\n          -  Concomitant neurologic conditions causing spasticity\n\n          -  Any medical condition, including psychiatric disease or epilepsy, which would\n             interfere with the interpretation of the trial results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027025", 
            "org_study_id": "CLR_11_03"
        }, 
        "intervention": [
            {
                "arm_group_label": "Baclofen Dose1", 
                "description": "Subjects randomized to this arm will receive Baclofen dose 1", 
                "intervention_name": "Baclofen dose 1", 
                "intervention_type": "Drug", 
                "other_name": "Baclofen low dose"
            }, 
            {
                "arm_group_label": "Baclofen dose 2", 
                "description": "Subjects randomized to this arm will receive Baclofen dose 2", 
                "intervention_name": "Baclofen dose 2", 
                "intervention_type": "Drug", 
                "other_name": "Baclofen high dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects will receive placebo capsules for once a day oral administration", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo capsules"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Baclofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Spasticity, Multiple sclerosis", 
        "lastchanged_date": "January 1, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial to Evaluate the Duration of Action of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis (MS)", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean change from Baseline in total Ashworth score assessed over 24 hours", 
            "measure": "Primary efficacy outcome: Improvement in Ashworth score", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subject's assessment of their overall spasm frequency", 
                "measure": "Spasm frequency", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 24 hours"
            }, 
            {
                "measure": "Nighttime awakening score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day24"
            }, 
            {
                "measure": "Clinical global impression of  change", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 24"
            }, 
            {
                "measure": "Subject's global impression of change", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 24"
            }, 
            {
                "measure": "Nighttime awakening score", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Day 23"
            }
        ], 
        "source": "Sun Pharma Advanced Research Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Pharma Advanced Research Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}